GlaxoSmithKline (LON:GSK) had its price objective decreased by equities researchers at JPMorgan Chase & Co. from GBX 1,500 ($19.60) to GBX 1,300 ($16.98) in a research note issued on Tuesday, price Targets.com reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s price target would indicate a potential upside of 2.51% from the company’s current price.
A number of other equities research analysts have also issued reports on the stock. Berenberg Bank reissued a “buy” rating and issued a GBX 1,720 ($22.47) price objective on shares of GlaxoSmithKline in a report on Tuesday, January 26th. Oddo Bhf set a GBX 1,490 ($19.47) price target on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a report on Thursday, February 4th. Morgan Stanley reiterated a “neutral” rating and issued a GBX 1,665 ($21.75) price objective on shares of GlaxoSmithKline in a report on Friday, November 13th. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline in a research note on Tuesday, January 26th. Finally, Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a GBX 1,150 ($15.02) target price on shares of GlaxoSmithKline in a research report on Thursday, February 4th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company. GlaxoSmithKline has an average rating of “Hold” and a consensus target price of GBX 1,671.33 ($21.84).
Shares of LON:GSK opened at GBX 1,268.11 ($16.57) on Tuesday. GlaxoSmithKline has a 52-week low of GBX 1,256.40 ($16.41) and a 52-week high of GBX 1,772.51 ($23.16). The stock has a market cap of £63.80 billion and a P/E ratio of 11.18. The business has a fifty day moving average of GBX 1,363.67 and a two-hundred day moving average of GBX 1,430.75. The company has a quick ratio of 0.63, a current ratio of 0.91 and a debt-to-equity ratio of 130.48.
In other GlaxoSmithKline news, insider Urs Rohner purchased 619 shares of the company’s stock in a transaction on Wednesday, February 3rd. The stock was acquired at an average price of GBX 1,361 ($17.78) per share, for a total transaction of £8,424.59 ($11,006.78). Also, insider Manvinder Singh Banga acquired 36,600 shares of the business’s stock in a transaction dated Wednesday, December 30th. The shares were bought at an average cost of GBX 1,376 ($17.98) per share, for a total transaction of £503,616 ($657,977.53). Insiders have acquired 37,237 shares of company stock worth $51,229,142 over the last quarter.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
See Also: What is a resistance level?